Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data - Scorecard - MDSpire
Clinical Scorecard: Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data
At a Glance
Category
Detail
Condition
Key Mechanisms
Combination therapies involving immune-checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, and tyrosine kinase inhibitors (TKIs) targeting VEGF.
Target Population
Care Setting
Key Highlights
Favorable risk patients show reduced disease progression risk with ICI-TKI combinations but no significant OS improvement over sunitinib in this subgroup.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess PFS and OS regularly, including specific metrics such as imaging frequency and clinical evaluations.
Risks
Patient & Prescribing Data
Monotherapy with TKIs remains a viable option for favorable risk patients, but consider potential side effects and patient preferences.
Clinical Best Practices
Incorporate patient risk stratification in treatment decision-making.
Regularly evaluate treatment responses and adjust strategies as necessary.
Involve a multidisciplinary team in treatment planning.
by Mattia Alberto Di Civita, Daniele Marinelli, Valerio Marco Michetti, Adele Artemi, Andrea Ballario, Andrea Torchia, Laura Pappalardo, Martina Pecoraro, Iolanda Speranza, Alessandro Sciarra, Valeria Panebianco, Michela Roberto, Daniele Santini
Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.
